Clinical research

Imara Announces First Patient Dosed in Ardent Phase 2b Clinical Trial of IMR-687 in Sickle Cell Disease

Retrieved on: 
Thursday, August 13, 2020

Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.

Key Points: 
  • Dosing of the first patient in the Ardent clinical trial represents a critical step forward as we advance IMR-687 into Phase 2b testing, a clinical trial that will test higher doses and longer durations of IMR-687, said Rahul Ballal, Ph.D., President and Chief Executive Officer of Imara.
  • Imara previously announced data from the second planned interim analysis of its ongoing Phase 2a clinical trial of IMR-687 in adult patients with SCD.
  • Imara expects to report top-line data from this Phase 2a clinical trial in the fourth quarter of 2020.
  • The global, randomized, double-blind, placebo-controlled, multicenter Ardent Phase 2b clinical trial will enroll approximately 99 adult patients with sickle cell disease (SCD).

For the 6th Time, BioPoint Inc. Appears on the Inc. 5000, Ranking No. 2867 With Three-Year Revenue Growth of 138.73%

Retrieved on: 
Thursday, August 13, 2020

2867 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies.

Key Points: 
  • 2867 on its annual Inc. 5000 list, the most prestigious ranking of the nation's fastest-growing private companies.
  • The list represents a unique look at the most successful companies within the American economy's most dynamic segmentits independent small businesses.
  • Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many other well-known names gained their first national exposure as honorees on the Inc. 5000.
  • Areas of expertise are pharmacovigilance, drug safety and risk management, regulatory affairs, market access, and clinical operations and biometrics.

Medidata Announces Launch of Medidata Detect, its Centralized Statistical Monitoring Solution for Clinical Trials

Retrieved on: 
Thursday, August 13, 2020

Medidata, a Dassault Systmes company, announced the launch of Medidata Detect, a centralized statistical monitoring solution that improves data quality and promotes patient safety in clinical trials for new medicines, vaccines and medical devices.

Key Points: 
  • Medidata, a Dassault Systmes company, announced the launch of Medidata Detect, a centralized statistical monitoring solution that improves data quality and promotes patient safety in clinical trials for new medicines, vaccines and medical devices.
  • Detect is another example of our continuous innovation that helps advance clinical trials with increased data accuracy and speed.
  • Medidata Detect identifies known and unknown risks, and triggers corrective actions, which proactively minimize study delays and submission failures in trials.
  • Medidata and Medidata Rave are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systmes.

AI in Drug Discovery Market by Component, Technology, Application, End User, and Geography - Global Opportunity Analysis and Industry Forecast to 2026 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 13, 2020

Another important factor of reducing the drug price has pressured the drug manufacturers to boost the production of AI for the drug discovery market.

Key Points: 
  • Another important factor of reducing the drug price has pressured the drug manufacturers to boost the production of AI for the drug discovery market.
  • Efficient working of AI reduced the failure rate of clinical trials and also eradicated the cost of length research and development in drug discovery.
  • Another factor which can bolster the anticipated growth of the Global AI for the drug discovery market is the lack of skilled health care professionals.
  • The report contains an understanding of technological innovations and advanced solutions for the AI in Drug Discovery.

4 Ways to Ensure the Success of Your COVID-19 Trial, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, August 13, 2020

Important questions have been raised concerning patient engagement, testing strategies, regulatory considerations, and operational aspects of these trials.

Key Points: 
  • Important questions have been raised concerning patient engagement, testing strategies, regulatory considerations, and operational aspects of these trials.
  • So, how can you ensure the success of your COVID-19 trial?
  • For more information or to register for this event, visit 4 Ways to Ensure the Success of Your COVID-19 Trial .
  • Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

Algernon Announces Enrollment of First U.S. Patient in Multinational Phase 2b/3 Human Study of Ifenprodil for Treatment of COVID-19

Retrieved on: 
Thursday, August 13, 2020

The Phase 2b/3 study enrollment target is 150 patients, aggregated from all participating sites.

Key Points: 
  • The Phase 2b/3 study enrollment target is 150 patients, aggregated from all participating sites.
  • We are very pleased to announce our first U.S. patient, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
  • The Companys multinational Phase 2b/3 human trial for COVID-19 is entitled, "A Randomized Open Label Phase 2b/3 Study of theSafety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patients with Confirmed COVID-19 Disease."
  • The data from the Phase 2b study will determine the number of patients needed to reach statistical significance in the Phase 3 trial.

Acasti Pharma Provides Business Update for the First Quarter of Fiscal 2021

Retrieved on: 
Thursday, August 13, 2020

We look forward to the unblinding of TRILOGY 2 data and reporting our findings, concurrent with a conference call update on or about August 31, 2020.

Key Points: 
  • We look forward to the unblinding of TRILOGY 2 data and reporting our findings, concurrent with a conference call update on or about August 31, 2020.
  • The Company believes it is sufficiently funded through the first calendar quarter of 2021, based on managements current projections.
  • As stated above, Acasti believes that current cash will fully fund the Companys operations through the first calendar quarter of 2021.
  • Acasti does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

Cerecor Announces Peer-Reviewed Publication Highlighting the Role of the Inflammatory Cytokine, LIGHT, in COVID-19 ARDS

Retrieved on: 
Thursday, August 13, 2020

This study is now well underway, and we expect topline results in the fourth quarter of 2020.

Key Points: 
  • This study is now well underway, and we expect topline results in the fourth quarter of 2020.
  • It offers the potential to treat cytokine release syndrome-induced COVID-19 ARDS in the near-term and broader ARDS indication beyond.
  • It is currently being developed as a treatment for pediatric Crohns disease and now cytokine release syndrome induced COVID-19 ARDS.
  • Cerecor is sponsoring a randomized, multicenter U.S., double-blind, placebo-controlled clinical study that will enroll approximately 82 subjects hospitalized with COVID-19 ARDS.

AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis

Retrieved on: 
Thursday, August 13, 2020

The trial will enroll approximately 30 CF patients with top line data from the study anticipated in 1H 2021.

Key Points: 
  • The trial will enroll approximately 30 CF patients with top line data from the study anticipated in 1H 2021.
  • Enrolling the first patient in our Phase 2b OPTION 2 trial is an important milestone and we appreciate the support from our clinical trial specialists and centers.
  • James Sapirstein, Chief Executive Officer of AzurRx, added, We are very pleased to announce that patient dosing in the OPTION 2 trial has begun in the U.S.
  • This represents an important milestone in the clinical development of MS1819 as an EPI monotherapy for patients with cystic fibrosis.

Global Systemic Mastocytosis Pipeline 2020 - Drugs, Companies, Clinical Trials, R&D Updates, Status and Outlook - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 13, 2020

The "Systemic Mastocytosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Mastocytosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • Good progress is anticipated during 2020 and 2021 with Systemic Mastocytosis pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials.
  • The Systemic Mastocytosis pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • The competitive intelligence report on Systemic Mastocytosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Systemic Mastocytosis pipeline.